| Schedule of Segment Reporting Information, by Segment [Table Text Block] |
| |
|
Quarter Ended |
|
|
Six Months Ended |
|
| |
|
December 31, |
|
|
December 31, |
|
| |
|
2020 |
|
|
2019 |
|
|
2020 |
|
|
2019 |
|
| Net sales: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Protein Sciences |
|
$ |
172,179 |
|
|
$ |
141,517 |
|
|
$ |
326,625 |
|
|
$ |
282,512 |
|
| Diagnostics and Genomics |
|
|
52,469 |
|
|
|
43,846 |
|
|
|
102,595 |
|
|
|
86,397 |
|
| Intersegment |
|
|
(395 |
) |
|
|
(429 |
) |
|
|
(768 |
) |
|
|
(732 |
) |
| Consolidated net sales |
|
$ |
224,253 |
|
|
$ |
184,934 |
|
|
$ |
428,452 |
|
|
$ |
368,177 |
|
| Operating income: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Protein Sciences |
|
$ |
80,246 |
|
|
$ |
60,872 |
|
|
$ |
150,598 |
|
|
$ |
120,410 |
|
| Diagnostics and Genomics |
|
|
8,107 |
|
|
|
975 |
|
|
|
16,781 |
|
|
|
1,875 |
|
| Segment operating income |
|
$ |
88,353 |
|
|
$ |
61,847 |
|
|
$ |
167,379 |
|
|
$ |
122,285 |
|
| Costs recognized on sale of acquired inventory |
|
|
(23 |
) |
|
|
- |
|
|
|
(23 |
) |
|
|
- |
|
| Amortization of acquisition related intangible assets |
|
|
(15,027 |
) |
|
|
(15,108 |
) |
|
|
(30,528 |
) |
|
|
(30,008 |
) |
| Acquisition related expenses |
|
|
(4,421 |
) |
|
|
881 |
|
|
|
(4,558 |
) |
|
|
(429 |
) |
| Stock based compensation |
|
|
(16,225 |
) |
|
|
(10,618 |
) |
|
|
(29,558 |
) |
|
|
(19,418 |
) |
| Restructure costs |
|
|
(142) |
|
|
|
- |
|
|
|
(142 |
) |
|
|
- |
|
| Corporate general, selling, and administrative expenses |
|
|
(1,520 |
) |
|
|
(12 |
) |
|
|
(2,482 |
) |
|
|
(2,113 |
) |
| Consolidated operating income |
|
$ |
50,995 |
|
|
$ |
36,992 |
|
|
$ |
100,087 |
|
|
$ |
70,317 |
|
|